Uncategorized

Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal

Published

on

The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version